Loading...
Ibalizumab: First Global Approval
TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and...
Saved in:
| Published in: | Drugs |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5988774/ https://ncbi.nlm.nih.gov/pubmed/29675744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-018-0907-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|